Hypercholesterolemia in rats impairs the cholinergic system and leads to memory deficits

Molecular and Cellular Neuroscience

Volumn 45, Issue 4, 2010, Pages 408-417

  Ullrich, Celine ^a   Pirchl, Michael ^a   Humpel, Christian ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Alzheimer's disease; Beta amyloid(1 42); Cholesterol; Cholinergic dysfunction; Hyperphosphorylated tau; In vivo; Inflammation; Memory impairment; Microbleeding

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; CD11B ANTIGEN; NERVE GROWTH FACTOR; TAU PROTEIN;

ALZHEIMER DISEASE; AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL INJURY; CHOLESTEROL BLOOD LEVEL; CHOLINERGIC NERVE CELL; CHOLINERGIC SYSTEM; CHRONIC BRAIN DISEASE; COGNITIVE DEFECT; CONTROLLED STUDY; HYPERCHOLESTEROLEMIA; IMMUNOREACTIVITY; INFLAMMATION; LEARNING DISORDER; LONG TERM MEMORY; MEMORY DISORDER; NONHUMAN; OLIVARY NUCLEUS; PRIORITY JOURNAL; RAT; SPATIAL MEMORY;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BLOTTING, WESTERN; BRAIN; CHOLESTEROL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HYPERCHOLESTEROLEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MAZE LEARNING; MEMORY DISORDERS; NEURONS; RATS; RATS, SPRAGUE-DAWLEY; TAU PROTEINS;

ANIMALIA; RATTUS;

EID: 77957959900     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2010.08.001     Document Type: Article

References (102)

1. Aihara N., Tanno H., Hall J.J., Pitts L.H., Noble L.J. Immunocytochemical loclization of immunoglobulins in the rat brain: relationship to the blood-brain barrier. J. Comp. Neurol. 1994, 342:481-496.
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S.T., Hampel H., Hull M., Landreth G., Lue L.-F., Mrak R., Mackenzie I.R., McGeer P.L., O'Bannion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 2000, 21:383-421.
3. Anstey K.J., Lipnicki D.M., Low L.F. Cholesterol as a risk factor for dementia and cognitive decline: a systematic review of prospective studies with meta-analysis. Am. J. Geriatr. Psychiatry 2008, 16:343-354.
4. Barnett J.V., Haigh L.S., Marsh J.D., Galper J.B. Effects of low density lipoproteins and mevinolin on sympathetic responsiveness in cultured chick atrial cells. J. Biol. Chem. 1989, 264:10779-10786.
5. Bell R.D., Zlokovic B.V. Neurovascular mechanisms and blood-brain barrier disorder in Alzheimer's disease. Acta Neuropathol. 2009, 118:103-113.
6. Biessels G.J., Bravenboer B., Gispen W.H. Glucose, insulin and the brain: modulation of cognition and synaptic plasticity in helath and disease: a preface. Eur. J. Pharmacol. 2004, 490:1-4.
7. Björkhem I. Do oxysterols control cholesterol homeostasis?. J. Clin. Invest. 2002, 110:725-730.
8. Björkhem I., Meaney S., Diczfalusy U. Oxysterols in human circulation: which role do they have?. Curr. Opin. Lipidol. 2002, 13:247-253.
9. Björkhem I., Heverin M., Leoni V., Meaney S., Diczfalusy U. Oxysterols and Alzheimer's disease. Acta Neurol. Scand. 2006, 114:43-49.
10. Blasko I., Lederer W., Oberbauer H., Walch T., Kemmler G., Hinterhuber H., Marksteiner J., Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement. Geriatr. Cogn. Disord. 2006, 21:9-15.
11. Bohr I. Hypercholesterolemic diet applied to rat dams protects their offspring against cognitive deficits. Simulated neonatal anoxia model. Physiol. Behav. 2004, 82:703-711.
12. Bojanic D.D., Tarr P.T., Gale G.D., Smith D.J., Bok D., Chen B., Nusinowitz S., Lövgren-Sandblom A., Björkhem I., Edwards P.A. Differential expression and function of ABCG1 and ABCG4 during development and ageing. J. Lipid Res. 2010, 5:169-181.
13. Böttger D., Ullrich C., Humpel C. Monocytes deliver bioactive nerve growth factor through a brain capillary endothelial cell-monolayer in vitro and counteract degeneration of cholinergic neurons. Brain Res. 2010, 1312:108-119.
14. Bowen D.M., Smith C.B., White P., Davison A.N. Neutoransmitter-related enzymes and indices of hypoxia in senile dementia and other abiotrophies. Brain 1976, 99:459-496.
15. Buxbaum J.D., Cullen E.I., Friedhoff L.T. Pharmacological concentrations of the HMG-CoA reductase inhibitor lovostatin decrease the formation of the Alzheimer beta-amyloid peptide in vitro and in patients. Front. Biosci. 2002, 7:50-59.
16. Candelario-Jalil E., Yang Y., Rosenberg G.A. Diverse roles of matrix metalloproteinases and tissue inhibitors of metalloproteinases in neuroinflammation and cerebral ischemia. Neuroscience 2009, 158:983-994.
17. Chen X., Gawryluk J.W., Wagener J.F., Ghribi O., Geiger J.D. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J. Neuroinflammation 2008, 5:12.
18. Covaceuszach S., Capsoni S., Ugolini G., Spirito F., Vignone D., Cattaneo A. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr. Alzheimer Res. 2009, 6:158-170.
19. Davies P., Maloney A.J. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 1976, 2:1403.
20. De Marinis E., Martini C., Trentalance A., Pallottini V. Sex differences in hepatic regulation of cholesterol homeostasis. J. Endocrinol. 2008, 198:635-643.
21. De Rosa R., Garcia A.A., Braschi C., Capsoni S., Maffei L., Berardi N., Cattaneo A. Intranasal administration of nerve growth factor (NGF) rescues recognition memory deficits in AD11 anti-NGF transgenic mice. Proc. Natl Acad. Sci. USA 2005, 102:3811-3816.
22. Dickstein D.l., Walsh J., Brautigam H., Stockton S.D., Gandy S., Hof P. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. J. Mt. Sinai Hosp. NY 2010, 77:82-102.
23. Dugas B., Charbonnier S., Baarine M., Ragot K., Delmas D., Ménétrier F., Lherminier J., Malvitte L., Khalfaoui T., Bron A., Creuzot-Garcher C., Latruffe N., Lizard G. Effects of oxysterols on cell viability, inflammatory cytokines, VEGF, and reactive oxygen species production on human retinal cells: cytoprotective effects and prevention of VEGF secretion by resveratrol. Eur. J. Nutr. 2010, PMID: 20339855 [Epub ahead of print].
24. Ehehalt R., Keller P., Haass C., Thiele C., Simons K. Amyloidogenic processing of the Alzheimer β-amyloid precursor protein depends on lipid rafts. J. Cell Biol. 2003, 160:113-123.
25. Eikelenboom P., van Gool W.A. Neuroinflammatory perspectives on the two faces of Alzheimer's disease. J. Neural Transm. 2004, 111:281-294.
26. Feron O., Kelly R.A. The caveolar paradox. Suppressing, inducing, and terminating eNOS signaling. Circ. Res. 2001, 88:129-131.
27. Fischer H.P., Marksteiner J., Ransmayer G., Saria A., Humpel C. NGF but not GDNF or Neurturin enhance acetylcholine tissue levels in striatal organotypic brain slices. Int. J. Dev. Neurosci. 1998, 16:391-401.
28. Foster T.C. Biological markers of age-related memory deficits: treatment of senescent physiology. CNS Drugs 2006, 20:153-166.
29. Friedhoff L.T., Cullen E.I., Geoghagen N.S., Buxbaum J.D. Treatment with controlled-release lovastatin decreases serum concentrations of human beta-amyloid (A beta) peptide. Int. J. Neuropsychopharmacol. 2001, 4:127-130.
30. Ghribi O. Potential mechanisms linking cholesterol to Alzheimer's disease-like pathology in rabbit brain, hippocampal organotypic slices, and skeletal muscle. J. Alzheimers Dis. 2008, 15:673-684.
31. Ghribi O., Larsen B., Schrag M., Herman M. High cholesterol content in neurons increases BACE, β-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp. Neurol. 2006, 200:460-467.
32. Granholm A.-C., Bimonte-Nelson H.A., Moore A.B., Nelson M.E., Freeman L.R., Sambamurti K. Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in the middle-aged rat. J. Alzheimers Dis. 2008, 14:133-145.
33. Greenwood C.E., Winocur G. Glucose treatment reduces memory deficits in young adult rats fed high-fat diets. Neurobiol. Learn. Mem. 2001, 75:179-189.
34. Greenwood C.E., Young S.N. Dietary fat intake and the brain: a developing frontier in biological psychiatry. J. Psychiatry Neurosci. 2002, 26:182-184.
35. Hazama G.-I., Yasuhara O., Morita H., Aimi Y., Tooyama I., Kimura H. Mouse brain IgG-like immunoreactivity: strain-specific occurrence in microglia and biochemical identification of IgG. J. Comp. Neurol. 2005, 492:234-249.
36. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur. J. Pharmacol. 2004, 490:115-125.
37. Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's disease. Neuroscience 2004, 5:347-360.
38. Ishii K., Tokuda T., Matsushima T., Miya F., Shoji S., Ikeda S., Tamaoka A. Pravastatin at 10mg/day does not decrease plasma levels of either amyloid-beta (Abeta) 40 or Abeta 42 in humans. Neurosci. Lett. 2003, 350:161-164.
39. Jarrard L.E., Okaichi H., Steward O., Goldschmidt R.B. On the role of hippocampal connections in the performance of place and cue tasks: comparisons with damage to hippocampus. Behav. Neurosci. 1984, 98:946-954.
40. Joffre C., Leclère L., Buteau B., Martine L., Cabaret S., Malvitte L., Acar N., Lizard G., Bron A., Creuzot-Garcher C., Bretillon L. Oxysterols induced inflammation and oxidation in primary porcine retinal pigment epithelial cells. Curr. Eye Res. 2007, 32:271-280.
41. Kandiah N., Feldman H.H. Therapeutic potential of statin in Alzheimer's disease. J. Neurol. Sci. 2009, 283:230-234.
42. Kivipelto M., Helkala E.-L., Laakso M.P., Hänninen T., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissien A. Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ 2001, 322:1447-1451.
43. Lemaire-Ewing S., Prunet C., Montange T., Vejux A., Berthier A., Bessède G., Corcos L., Gambert P., Nèel D., Lizard G. Comparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterols. Cell Biol. Toxicol. 2005, 21:97-114.
44. Levin-Allerhand J.A., Lominska C.E., Smith J.D. Increased amyloid-β levels in APPSWE transgenic mice treated chronically with a physiological high-fat high-cholesterol diet. J. Nutr. Health Aging 2002, 6:315-319.
45. Liu R.Y., Gu R., Qi X.L., Zhang T., Zhao Y., He Y., Pei J.J., Guan Z.Z. Decreased nicotinic receptors and cognitive deficit in rats intracerebroventricularly injected with beta-amyloid peptide(1-42) and fed a high-cholesterol diet. J. Neurosci. Res. 2008, 86:183-193.
46. Longo F.M., Massa S.M. Neuroprotective strategies in Alzheimer's disease. NeuroRx 2004, 1:117-127.
47. Lucas S.-M., Rothwell N.J., Gibson R.M. The role of inflammation in CNS injury and disease. Br. J. Pharmacol. 2006, 147:232-240.
48. Marksteiner J., Humpel C. Beta-amyloid expression, release and extracellular deposition in aged rat brain slices. Mol. Psychiatry 2008, 13:939-952.
49. Marksteiner J., Kemmler G., Weiss E.M., Knaus G., Ullrich C., Mechteriakov S., Oberbauer H., Auffinger S., Hinterhölzl J., Hinterhuber H., Humpel C. Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 2009, PMID: 19395124 [Epub ahead of print].
50. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984, 34:939-944.
51. McKinney M. Brain cholinergic vulnerability: relevance to behavior and disease. Biochem. Pharmacol. 2005, 70:1115-1124.
52. McLin D.E., Miasnikov A.A., Weinberger N.M. Induction of behavioral associative memory by stimulation of the nucleus basalis. PNAS 2002, 99:4002-4007.
53. Mesulam M. The cholinergic lesion of Alzheimer's disease: pivotal factor or side show?. Learn. Mem. 2010, 11:43-49.
54. Miklossy J. Cerebral hypoperfusion induces cortical watershed microinfarcts which may further aggravate cognitive decline in Alzheimer's disease. Neurol. Res. 2003, 25:605-610.
55. Molteni R., Barnard R.J., Ying Z., Roberts C.K., Gómez-Pinilla F. A high-fat, refined sugar diet reduces hippocampal brain-derived neurotrophic factor, neuronal plasticity, and learning. Neuroscience 2002, 112:803-814.
56. Morello F., Saglio E., Noghero A., Schiavone D., Williams T.A., Verhove A., Bussolino F., Veglio F., Mulatero P. LXR-activating oxysterols induce the expression of inflammatory markers in endothelial cells through LXR-independent mechanisms. Atherosclerosis 2009, 207:38-44. d.
57. Moser K.V., Schmidt-Kastner R., Hinterhuber H., Humpel C. Brain capillaries and cholinergic neurons persist in organotypic brain slices in the absence of blood flow. Eur. J. Neurosci. 2003, 18:85-94.
58. Mufson E.J., Ginsberg S.D., Ikonomovic M.D., DeKosky S.T. Human cholinergic basal forebrain: chemoanatomy and neurologic dysfunction. J. Chem. Neuroanat. 2003, 26:233-242.
59. Nicholson A.M., Ferreira A. Increased membrane cholesterol might render mature hippocampal neurons more susceptible to β-amyloid-induced calpain activation and tau toxicity. J. Neurosci. 2009, 29:4640-4651.
60. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 1986, Academic Press, Australia. 2nd ed.
61. Pfrieger F.W. Role of cholesterol in synapse formation and function. Biochem. Biophys. Acta 2003, 1610:271-280.
62. Pizzo D.P., Thal L.J., Winkler J. Mnemonic deficits in animals depend upon the degree of cholinergic deficit and task complexicity. Exp. Neurol. 2002, 177:292-305.
63. Prasanthi J., Schommer E., Thomasson S., Thompson A., Feist G., Ghribi O. Regulation of β-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech. Ageing Dev. 2008, 129:649-655.
64. Prasanthi J., Huls A., Thomasson S., Thomspon A., Schommer E., Ghribi O. Differential effects of 24-hydroxycholesterol and 27-hydroxycholesterol on β-amyloid precursor protein levels and processing in human neuroblastoma SH-SY5Y cells. Mol. Neurodegener. 2009, 4:1.
65. Prunet C., Montange T., Véjux A., Laubriet A., Rohmer J.-F., Riedinger J.-M., Athias A., Lemaire-Ewing S., Néel D., Petit J.-M., Steinmetz E., Brenot R., Gambert P., Lizard G. Multiplexed flow cytometric analysis of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of Atherosclerotic patients. Cytom. A 2006, 69:359-373.
66. Puglielli L., Tanzi R.E., Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 2003, 6:345-351.
67. Raffai R.L., Weisgraber K.H. Cholesterol: from heart attack to Alzheimer's disease. J. Lipid Res. 2003, 44:1423-1430.
68. Rahman S.M.A., Van Dam A.-M., Schultzberg M., Crisby M. High cholesterol diet results in increased expression of interleukin-6 and caspase-1 in the brain of apolipoprotein E knockout and wild type mice. J. Neuroimmunol. 2005, 169:59-67.
69. Refolo L.M., Pappolla M.A., Malester B., LaFrancois J., Bryant-Thomas T., Wang R., Tint G.S., Sambamurti K., Duff K. Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol. Dis. 2000, 7:321-331.
70. Rogers J. The inflammatory response in Alzheimer's disease. J. Periodontol. 2008, 79:1535-1543.
71. Rosklint T., Ohlsson B.G., Wiklund O., Norén K., Hultén L.M. Oxysterols induce interleukin-1β production in human macrophages. Eur. J. Clin. Invest. 2002, 32:35-42.
72. Sassin I., Schultz C., Thal D.R., Rüb U., Arai K., Braak E., Braak H. Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol. 2000, 100:259-269.
73. Schindowski K., Belarbi K., Buée L. Neurotrophic factors in Alzheimer's disease: role of axonal transport. Genes Brain Behav. 2008, 7:43-56.
74. Schliebs R., Arendt T. The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J. Neural Transm. 2006, 113:1625-1644.
75. Schmidt-Kastner R., Meller D., Bellander B.M., Strömberg I., Olson L., Ingvar M. A one-step immunohistochemical method for detection of blood-brain barrier disturbances for immunoglobulins in lesioned rat brain with special reference to false-positive labelling in immunohistochemistry. J. Neurosci. Methods 1993, 46:121-132.
76. Serrano-Pozo A., Vega G.L., Lütjohann D., Lacascio J.J., Tennis M.K., Deng A., Atri A., Hyman B.T., Irizarry M.C., Growdon J.H. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis. Assoc. Disord. 2010, PMID:20473136 [Epub ehead of print].
77. Sharma S., Prasanthi J., Schommer E., Feist G., Ghribi O. Hypercholesterolemia-induced Aβ accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol. Dis. 2008, 32:426-432.
78. Shobab L.A., Hsiung G.-Y.R., Feldman H.H. Cholesterol in Alzheimer's disease. Lancet Neurol. 2005, 4:841-852.
79. Simons M., Keller P., Dichgans J., Schulz J.B. Cholesterol and Alzheimer's disease. Is there a link. Neurology 2001, 57:1089-1093.
80. Sottero B., Gamba P., Garguilo S., Leonarduzzi G., Poli G. Cholesterol oxidation products and disease: an emerging topic of interest in medical chemistry. Curr. Med. Chem. 2009, 16:685-705.
81. Sparks D.L., Scheff S.W., Hunsaker J.C., Liu H., Landers T., Gross D.R. Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 1994, 126:88-94.
82. Sparks D.L., Kuo Y.-M., Roher A., Martin T., Lukas R. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Ann. NY Acad. Sci. 2000, 903:335-344.
83. Srinivasan K., Patole P.S., Kaul C.L., Ramarao P. Reversal of glucose intolerance by pioglitazone in high fat diet-fed rats. Methods Find. Exp. Clin. Pharmacol. 2004, 26:327-333.
84. Stolp H.B., Dziegielewska K.M. Review: role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative disease. Neuropathol. Appl. Neurobiol. 2009, 35:132-146.
85. Stuchbury G., Münch G. Alzheimer's associated inflammation, potential drug targets and future therapies. J. Neural Transm. 2005, 112:429-453.
86. Suter O.C., Sunthorn T., Kraftsik R., Straubel J., Darekar P., Khalili K., Miklossy J. Cerebral hypoperfusion generates cortical watershed microinfarcts in Alzheimer disease. Stroke 2002, 33:1986-1992.
87. Thirumangalakudi L., Prakasam A., Zhang R., Bimonte-Nelson H., Sambamurti K., Kindy M.S., Bhar N.R. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with loss of working memory in mice. J. Neurochem. 2008, 106:475-485.
88. Tong X.K., Nicolakakis N., Fernandes P., Ongali B., Brouilette J., Quirion R., Hamel E. Simvastatin improves cerebrovascular function and counters soluble amyloid-beta, inflammation and oxidative stress in aged APP mice. Neurobiol. Dis. 2009, 35:406-414.
89. Trousson A., Bernard S., Petit P.X., Liere P., Pianos A., El Hadri K., Lobaccaro J.-M.A., Ghandour M.S., Raymondjean M., Schumacher M., Massaad C. 25-hydroxycholesterol provokes oligodendrocyte cell line apoptosis and stimulates the secreted phospholipase A2 type IIA via LXR beta and PXR. J. Neurochem. 2009, 109:945-958.
90. Ullrich C., Humpel C. The pro-apoptotic substance thapsigargin selectively stimulates re-growth of brain capillaries. Curr. Neurovasc. Res. 2009, 6:171-180.
91. Ullrich C., Humpel C. Effects of cholesterol and its 24S-OH and 25-OH oxysterols on choline acetyltransferase-positive neurons in brain slices. Pharmacology 2010, 86:15-21.
92. Vejux A., Malvitte L., Lizard G. Side effects of oxysterols: cytotoxicity, oxidation, inflammation, and phospholipidosis. Braz. J. Med. Biol. Res. 2008, 41:545-556.
93. Vogels O.J., Broere C.A., ter Laak H.J., ten Donelaar H.J., Nieuwenhuys R., Schulte B.P. Cell loss and shrinkage in the nucleus basalis Meynert complex in Alzheimer's disease. Neurobiol. Aging 1990, 11:3-13.
94. Webb L.E., Lengle E., Izzo R., Woods E. Micromethod for liquid-chromatographic determination of cholesterol in lipemic sera. Clin. Chem. 1982, 28:1769-1772.
95. Wellington C.L. Cholesterol at the crossroads: Alzheimer's disease and lipid metabolism. Clin. Genet. 2004, 66:1-16.
96. Wenk G.L. The nucleus basalis magnocellularis cholinergic system: one hundred years of progress. Neurobiol. Learn. Mem. 1997, 67:85-95.
97. Winkler J., Suhr S.T., Gage F.H., Thal L.J., Fisher L.J. Essential role of neocortical acetylcholine in spatial memory. Nature 1995, 375:484-487.
98. Winkler J., Thal L.J., Gage F.H., Fisher L.J. Cholinergic strategies for Alzheimer's disease. J. Mol. Med. 1998, 76:555-567.
99. Winocur G., Greenwood C.E. The effects of high fat diets and environmental influences on cognitive performance in rats. Behav. Brain Res. 1999, 101:153-161.
100. Xie C., Lund E.G., Turley S.D., Russell D.W., Dietschy J.M. Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J. Lipid Res. 2003, 44:1780-1789.
101. Xue Q.-S., Sparks D.L., Streit W. Microglial activation in the hippocampus of hypercholesterolemic rabbits occurs independent of increased amyloid production. J. Neuroinflammation 2007, 4:20.
102. Zassler B., Humpel C. Transplantation of NGF secreting primary monocytes counteracts NMDA-induced cell death of rat cholinergic neurons in vivo. Exp. Neurol. 2006, 198:391-400.